IRISH biotech company Elan sold an 18pc stake in US drug firm Alkermes for $381m (€291m).
The deal secures three-quarters of the company's holding as Elan received a 25pc stake in Alkermes plus €500m last year in exchange for its Athlone-based drug delivery business.
Elan sold the shares after a six-month lock-up period.